SG11201504340YA - Treatment of diseases of endothelial dysfunction and inflammation - Google Patents

Treatment of diseases of endothelial dysfunction and inflammation

Info

Publication number
SG11201504340YA
SG11201504340YA SG11201504340YA SG11201504340YA SG11201504340YA SG 11201504340Y A SG11201504340Y A SG 11201504340YA SG 11201504340Y A SG11201504340Y A SG 11201504340YA SG 11201504340Y A SG11201504340Y A SG 11201504340YA SG 11201504340Y A SG11201504340Y A SG 11201504340YA
Authority
SG
Singapore
Prior art keywords
inflammation
diseases
treatment
endothelial dysfunction
dysfunction
Prior art date
Application number
SG11201504340YA
Other languages
English (en)
Inventor
Silviu Itescu
Peter Ghosh
Wayne Gregory Kimpton
Simon Reeves Bailey
Original Assignee
Mesoblast Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast Inc filed Critical Mesoblast Inc
Publication of SG11201504340YA publication Critical patent/SG11201504340YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
SG11201504340YA 2012-12-12 2013-12-12 Treatment of diseases of endothelial dysfunction and inflammation SG11201504340YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736361P 2012-12-12 2012-12-12
PCT/AU2013/001452 WO2014089623A1 (en) 2012-12-12 2013-12-12 Treatment of diseases of endothelial dysfunction and inflammation

Publications (1)

Publication Number Publication Date
SG11201504340YA true SG11201504340YA (en) 2015-07-30

Family

ID=50933585

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201504340YA SG11201504340YA (en) 2012-12-12 2013-12-12 Treatment of diseases of endothelial dysfunction and inflammation
SG10201705061RA SG10201705061RA (en) 2012-12-12 2013-12-12 Treatment of Diseases of Endothelial Dysfunction and Inflammation

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201705061RA SG10201705061RA (en) 2012-12-12 2013-12-12 Treatment of Diseases of Endothelial Dysfunction and Inflammation

Country Status (11)

Country Link
US (2) US20160175360A1 (enExample)
EP (2) EP2931876B1 (enExample)
JP (5) JP6572130B2 (enExample)
KR (3) KR102217962B1 (enExample)
CN (2) CN105358163B (enExample)
AU (4) AU2013360024B2 (enExample)
CA (1) CA2893942C (enExample)
ES (1) ES2742035T3 (enExample)
IL (1) IL239308A0 (enExample)
SG (2) SG11201504340YA (enExample)
WO (1) WO2014089623A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101995016B1 (ko) 2007-12-04 2019-06-28 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절
SG11201504340YA (en) * 2012-12-12 2015-07-30 Mesoblast Inc Treatment of diseases of endothelial dysfunction and inflammation
WO2022114111A1 (ja) * 2020-11-27 2022-06-02 マルホ株式会社 医薬品又は化粧品用組成物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
WO1998043630A1 (en) * 1997-04-02 1998-10-08 Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
DE19939781C2 (de) 1999-08-21 2003-06-18 Schott Glas Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
TR201900968T4 (tr) 2004-09-24 2019-02-21 Mesoblast Inc Multipotansiyel genleşmiş mezenkimal prekürsör hücre soyu (memp) ve bunların kullanımı.
US8367405B2 (en) 2005-04-12 2013-02-05 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
US20080241112A1 (en) 2005-05-10 2008-10-02 Christof Westenfelder Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media
US20080260703A1 (en) * 2007-04-23 2008-10-23 Medistem Labortories Treatment of Insulin Resistance and Diabetes
WO2009073594A1 (en) * 2007-11-30 2009-06-11 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
EP2227238A2 (en) * 2007-11-30 2010-09-15 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
KR101995016B1 (ko) * 2007-12-04 2019-06-28 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절
WO2010005527A1 (en) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
CN104546912B (zh) * 2008-11-20 2019-11-08 中胚有限公司 用于治疗胰功能异常的方法
WO2010138180A2 (en) * 2009-05-26 2010-12-02 The University Of Vermont And State Agriculture College Compositions and methods for cardiac tissue repair
WO2011073521A1 (en) * 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
US20120195969A1 (en) * 2010-09-29 2012-08-02 Aidan Research And Consulting, Llc Treatment of acne by conditioned media
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
EP2714057B1 (en) * 2011-06-03 2019-11-06 Mesoblast, Inc. Methods of treating or preventing neurological diseases
US9265796B2 (en) * 2011-07-04 2016-02-23 Mesoblast, Inc. Methods of treating or preventing rheumatic disease
CN104684561A (zh) * 2012-08-01 2015-06-03 联合治疗公司 利用间充质干细胞的肺动脉高血压的治疗
SG11201504340YA (en) * 2012-12-12 2015-07-30 Mesoblast Inc Treatment of diseases of endothelial dysfunction and inflammation
KR102466885B1 (ko) * 2013-01-09 2022-11-11 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린 및 중간엽 줄기 세포를 사용한 혈관병증의 치료

Also Published As

Publication number Publication date
CA2893942A1 (en) 2014-06-19
SG10201705061RA (en) 2017-07-28
KR102367981B1 (ko) 2022-02-25
EP2931876A1 (en) 2015-10-21
IL239308A0 (en) 2015-07-30
AU2019202960B2 (en) 2021-07-29
HK1210209A1 (en) 2016-04-15
CA2893942C (en) 2023-03-28
JP6572130B2 (ja) 2019-09-04
KR102506612B1 (ko) 2023-03-06
WO2014089623A1 (en) 2014-06-19
US20240115618A1 (en) 2024-04-11
KR102217962B1 (ko) 2021-02-22
JP2019214571A (ja) 2019-12-19
KR20220029758A (ko) 2022-03-08
AU2019202960A1 (en) 2019-05-16
EP2931876B1 (en) 2019-05-29
KR20150093732A (ko) 2015-08-18
EP3556850A1 (en) 2019-10-23
CN105358163A (zh) 2016-02-24
AU2024227208A1 (en) 2024-10-31
AU2013360024B2 (en) 2019-02-28
CN105358163B (zh) 2020-09-11
CN111840329B (zh) 2024-10-15
JP2016504311A (ja) 2016-02-12
ES2742035T3 (es) 2020-02-12
JP6829288B2 (ja) 2021-02-10
AU2021250848A1 (en) 2021-11-04
JP2023030116A (ja) 2023-03-07
KR20210021104A (ko) 2021-02-24
JP7201715B2 (ja) 2023-01-10
US20160175360A1 (en) 2016-06-23
JP2021073240A (ja) 2021-05-13
JP2024147655A (ja) 2024-10-16
CN111840329A (zh) 2020-10-30
AU2013360024A1 (en) 2015-07-02
EP2931876A4 (en) 2016-05-25

Similar Documents

Publication Publication Date Title
ZA202100373B (en) Therapeutically active compounds and their methods of use
IL261768B (en) Devices and methods for tissue treatment
IL237070B (en) Treatment of vaccine-related diseases and inflammatory diseases
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
ZA201402615B (en) Prevention and treatment of ocular conditions
ZA201405163B (en) Therapeutically active compounds and their methods of use
EP2804850A4 (en) THERAPEUTIC ACTIVE SUBSTANCES AND METHOD FOR THEIR USE
IL233111A0 (en) Preparations for the treatment of inflammation
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
PL2668182T3 (pl) Inhibitowanie IL17 i IFN-gamma do leczenia zapalenia autoimmunologicznego
PT2668183T (pt) Inibição de il-7 e de ifn gama para o tratamento de inflamação autoimune
EP2869833A4 (en) TREATMENT OF INFLAMMATORY SKIN DISORDERS
EP2574172A4 (en) MATERIALS AND METHOD FOR TREATING INFLAMMATION
ZA201503979B (en) Treatment of diseases involving mucin
LT2827883T (lt) Tfpi inhibitoriai ir jų panaudojimo būdai
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
IL233080B (en) Bisarylsulfonamides used to treat inflammation and cancer
ZA201401800B (en) Novel plant defensins and use in the treatment of proliferative diseases
IL239308A0 (en) Treatment of diseases of endothelial dysfunction and inflammation
PL2744497T3 (pl) Terapeutyczne połączenia netupitantu i palonosetronu
GB201100651D0 (en) Treatment of inflammation
AU2012900272A0 (en) Treatment and inhibition of corneal erosions
GB201201779D0 (en) Treatment of inflammatory disorders
AU2012901301A0 (en) Treatment of inflammatory and immune disorders